Marketplace®

Daily business news and economic stories
Donate

404 - Page Not Found

The page you are looking for does not exist.

Go to Homepage
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

5.765 +0.015 (+0.26%)
Streaming Delayed Price Updated: 11:39 AM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,170,999
Open 5.620
Bid (Size) 5.760 (31)
Ask (Size) 5.770 (42)
Prev. Close 5.750
Today's Range 5.540 - 5.840
52wk Range 3.790 - 12.36
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Monster Stocks to Hold for the Next 10 Years
They're not just leaders of their industry. Their underlying businesses are also on the verge of enormous growth. 
Via The Motley Fool
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
From Recursion Pharmaceuticals
Via GlobeNewswire

Performance

YTD
-20.0%
-20.0%
1 Month
-11.7%
-11.7%
3 Month
-23.4%
-23.4%
6 Month
-9.4%
-9.4%
1 Year
-27.4%
-27.4%

More News

Read More
This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy?
Via The Motley Fool
Topics Animal Testing Artificial Intelligence Intellectual Property
Exposures Animal Testing Artificial Intelligence Intellectual Property
Why Recursion Pharmaceuticals Stock Is Sinking Today
Via The Motley Fool
Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News
Via Stocktwits
Topics Animal Testing Artificial Intelligence Stocks
Exposures Animal Testing Artificial Intelligence Product Safety
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing
Via Benzinga
Topics Animal Testing
Exposures Animal Testing Product Safety
Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX
Via Stocktwits
Topics Animal Testing
Exposures Animal Testing Product Safety
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio?
Via Benzinga
The market is filled with gapping stocks in Friday's session.
Via Chartmill
Why Recursion Pharmaceuticals Stock Is Skyrocketing Today
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
Exposures Animal Testing Artificial Intelligence Product Safety
Recursion Pharmaceuticals Shares Are Up Today: what's Going On?
Via Benzinga
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Nvidia-Backed Recursion Pharma Soars After-Hours As FDA Eyes AI Over Animal Testing For Drugs: Retail Traders Elated
Via Stocktwits
Topics Animal Testing Artificial Intelligence
Exposures Animal Testing Artificial Intelligence Product Safety
Wondering what's happening in today's after-hours session?
Via Chartmill
Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements
Via Benzinga
Topics Animal Testing
Exposures Animal Testing Product Safety
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
From Recursion Pharmaceuticals
Via GlobeNewswire
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
Via The Motley Fool
Topics Bankruptcy Economy World Trade
Exposures Economy Financial Legal
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
Via The Motley Fool
Topics Government World Trade
Exposures COVID-19 Political Product Safety
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Nvidia Has 81% of Its $304 Million Stock Portfolio Invested in 3 Groundbreaking AI Stocks
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
From Recursion Pharmaceuticals
Via GlobeNewswire

Frequently Asked Questions

Is Recursion Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Recursion Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Recursion Pharmaceuticals, Inc. - Class A Common Stock trade on?
Recursion Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock is RXRX on the Nasdaq Stock Market
What is the current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 5.765
When was Recursion Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Recursion Pharmaceuticals, Inc. - Class A Common Stock was at 04/25/25 11:39 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.